 "Sales decline in US pushing drug makers to evaluate option in Europe")
Slowdown in sales due to drug price erosion in the US is pushing home-grown pharmaceutical companies to evaluate opportunities in Europe.
Europe is the third-largest market for Indian drug makers after the US and Africa. Data from IQVIA says that at $35 billion, the European generics market is the world’s second-largest by value after the US. Thus, it is an attractive market for most Indian firms.
Among them is Ahmedabad-based Torrent Pharmaceuticals. The firm is in the race to buy Sanofi’s European generics business. Indian peers Intas, Zydus Cadila and Aurobindo Pharma are also in the fray, but
Europe is the third-largest market for Indian drug makers after the US and Africa. Data from IQVIA says that at $35 billion, the European generics market is the world’s second-largest by value after the US. Thus, it is an attractive market for most Indian firms.
Among them is Ahmedabad-based Torrent Pharmaceuticals. The firm is in the race to buy Sanofi’s European generics business. Indian peers Intas, Zydus Cadila and Aurobindo Pharma are also in the fray, but
